Antibodies, or immunoglobulins (Igs), are glycoproteins produced by plasma cells as part of the adaptive immune response. They are composed of two identical heavy chains (~50 kDa each) and two identical light chains (~25 kDa each), connected by disulfide bonds to form a Y-shaped quaternary structure. Each chain contains a variable (V) region and a constant (C) region.
The antibody molecule is functionally divided into two major regions:
Fab (Fragment antigen-binding): Contains the variable domains and is responsible for antigen binding.
Fc (Fragment crystallizable): Comprises the constant domains of the heavy chains and mediates interactions with immune effector molecules and cells.
This architectural division allows antibodies to perform two core tasks: high-specificity antigen recognition and initiation of downstream immune functions; through structurally and functionally distinct modules.
The Fab region is formed by the complete light chain (variable and constant domains: VL and CL) and the N-terminal part of the heavy chain (VH and CH1). Together, the VH and VL domains form the antigen-binding site. These regions contain three hypervariable loops known as complementarity-determining regions (CDRs), which directly interact with the antigen’s epitope via non-covalent forces.
Each IgG molecule possesses two Fab arms, enabling bivalent antigen binding. This bivalency enhances avidity and permits effective cross-linking of multivalent antigens, a critical feature in immune complex formation.
During B-cell maturation, somatic hypermutation in the V regions introduces point mutations into the CDRs. Combined with affinity maturation, this process ensures that the Fab domain evolves for optimal specificity and affinity.
Notably, the Fab domain is highly flexible at the hinge and the V-C junction. This structural flexibility enables the Fab arms to orient and engage with spatially distinct epitopes on the same or different antigens, increasing functional versatility.
The Fc region is composed of the CH2 and CH3 domains (CH2–CH3–CH2–CH3 dimer) in IgG, IgA, and IgD, and includes an additional CH4 domain in IgM and IgE. Unlike the Fab region, the Fc does not interact with antigens directly. Instead, it binds to various Fc receptors (FcRs) on immune cells and to complement proteins, thereby initiating effector functions.
Key Fc-mediated functions include:
Antibody-Dependent Cellular Cytotoxicity (ADCC): FcγRIIIa on natural killer (NK) cells binds IgG-opsonized targets, triggering cytotoxic granule release.
Complement-Dependent Cytotoxicity (CDC): The Fc domain binds complement component C1q, activating the classical complement pathway and leading to target cell lysis.
Opsonophagocytosis: Binding of the Fc domain to FcRs on macrophages or neutrophils enhances phagocytic clearance of antibody-coated pathogens.
Glycosylation at the conserved N297 site in the CH2 domain modulates Fc conformation and receptor binding affinity. Variations in glycosylation profiles significantly influence the Fc region’s effector function, pharmacokinetics, and immunogenicity.
Fc-mediated immune modulation is also influenced by genetic polymorphisms in Fc receptors. The CD16A-158V/V variant, for example, has higher affinity for IgG1 and IgG3 compared to the 158F/F variant, improving therapeutic efficacy in ADCC-driven applications.
Importantly, different IgG subclasses (e.g., IgG1, IgG2, IgG3, IgG4) exhibit distinct Fc structures and affinities for Fcγ receptors, leading to subclass-specific immune outcomes.
Related: Antibody Formats: Antibody fragments (Fab, F(ab')2, Fc)
Although structurally distinct, Fab and Fc domains are not functionally independent. Antigen binding by the Fab can induce allosteric changes in the Fc region, potentially modulating FcγR binding and downstream immune responses. Similarly, interactions with Fc receptors may influence the overall conformation of the antibody.
Recent studies have demonstrated that the Fab domain contributes directly to Fcγ receptor binding, particularly in the case of FcγRIIIa. Using high-speed atomic force microscopy (HS-AFM) and hydrogen-deuterium exchange mass spectrometry (HDX-MS), researchers have observed that the Fab domain participates in receptor interaction in addition to the canonical Fc-mediated engagement.
These findings suggest that therapeutic antibody engineering should consider not only Fc optimization but also Fab-Fc synergy, particularly for antibodies intended to mediate cytotoxic functions via FcγR engagement.
Understanding the distinct and combined roles of Fab and Fc regions is central to designing antibodies with tailored therapeutic mechanisms.
Neutralizing Antibodies: These rely primarily on high-affinity Fab regions to block pathogen entry or neutralize toxins. Examples include anti-viral antibodies against influenza, RSV, or SARS-CoV-2.
Depleting Antibodies: These depend on Fc-mediated effector functions to eliminate target cells via ADCC or CDC. For instance, anti-CD20 antibodies used in B-cell malignancies are designed for strong FcγR engagement.
Bispecific Antibodies: Engineered to contain two different Fab domains, enabling dual antigen targeting. These often retain an Fc region for half-life extension and immune recruitment.
Antibody-Drug Conjugates (ADCs): Incorporate a cytotoxic payload linked to the Fab or Fc region. The Fc domain ensures serum stability and uptake via FcRn-mediated recycling.
Diagnostic Antibodies: In diagnostic assays, Fab specificity ensures target detection, while Fc modifications can improve signal detection or conjugation to detection moieties.
From a production standpoint, the structural complexity of Fab and Fc domains presents several engineering and expression challenges.
Expression Systems
CHO (Chinese Hamster Ovary) cells remain the industry standard for recombinant IgG production due to their capacity for complex post-translational modifications, including Fc glycosylation.
HEK293 cells are frequently used in early-stage research or for producing Fab fragments lacking Fc regions.
Folding and Stability
Proper folding of the variable domains in the Fab region is essential for antigen recognition. Misfolding can result in aggregation or loss of function.
The Fc region’s stability and glycosylation profile are critical for maintaining effector function and pharmacokinetics.
Fc Engineering
Mutagenesis of Fc residues (e.g., at the CH2 domain) can modulate binding affinity to FcγRs or eliminate effector function (as in effector-silent antibodies).
Glycoengineering allows for control of Fc glycan structures, enabling enhancement or attenuation of ADCC and CDC.
Fab Modifications
Engineering CDRs via display technologies (e.g., phage, yeast, or mammalian display) is a standard strategy for improving antigen-binding affinity and specificity.
Truncated or single-chain variants (e.g., scFv) are often employed in tissue-penetrating therapies or as components of bispecific antibodies.
Advancing antibody research requires access to reliable, rapid expression platforms. Biointron’s RushMab™ service provides small-scale, high-quality recombinant antibodies and plasmids within 4-10 days for fast production. With multiple package options—RushMab™-Gene (4-day plasmid delivery), RushMab™-Super (8-day supernatant plus plasmids), RushMab™-Mini (10-day purified antibody ≥100 µg), and RushMab™-Standard (10-day purified antibody ≥1 mg)—the platform supports efficient production of antibodies. Backed by more than 12 years of experience and the delivery of over 100,000 recombinant antibodies annually to global partners, Biointron ensures the speed, quality, and scalability essential for your research programs.
References:
Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. The structure of a typical antibody molecule. Available from: https://www.ncbi.nlm.nih.gov/books/NBK27144/
Yogo, R., Yamaguchi, Y., Watanabe, H., Yagi, H., Satoh, T., Nakanishi, M., Onitsuka, M., Omasa, T., Shimada, M., Maruno, T., Torisu, T., Watanabe, S., Higo, D., Uchihashi, T., Yanaka, S., Uchiyama, S., & Kato, K. (2019). The Fab portion of immunoglobulin G contributes to its binding to Fcγ receptor III. Scientific Reports, 9, 11957. https://doi.org/10.1038/s41598-019-48323-w
Artificial intelligence has greatly improved therapeutic antibody development, n……
Antibody affinity is a core metric in immunology and biopharmaceutical science. ……
A roundup of the biggest antibody biotech and pharma deals in December 2025.
The antibody therapeutics landscape continues to evolve rapidly, with 2026 marki……
You can also contact us on the Scientist and Science Exchange marketplaces.
